Desiree Nelson, APRN
Family · Fayetteville, ARNPI 1992396915
Payments from drug & device makers
Across 311 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$951
- AstraZeneca$666
- Sanofi$506
- Boehringer Ingelheim$430
- AbbVie$370
- Regeneron Healthcare Solutions, Inc.$355
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,07497%
- Education$1573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $951 |
| AstraZeneca(2 entities) | 28 | $666 |
| Sanofi | 27 | $506 |
| Boehringer Ingelheim | 29 | $430 |
| AbbVie | 33 | $370 |
| Regeneron Healthcare Solutions, Inc. | 14 | $355 |
| Amgen | 13 | $245 |
| Pfizer | 17 | $221 |
| Actelion Pharmaceuticals US, Inc. | 9 | $209 |
| Insmed, Inc. | 9 | $178 |
| CSL Behring | 9 | $162 |
| Biohaven Pharmaceuticals, Inc. | 18 | $154 |
| Intuitive Surgical | 1 | $134 |
| Grifols USA, LLC | 8 | $133 |
| Lilly USA, LLC | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| UCB, Inc. | 3 | $48 |
| Harmony Biosciences LLC | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| Electromed, Inc. | 2 | $31 |
| 3b Medical, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Biogen | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Abiomed | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Novo Nordisk | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$203
- BEVESPI AEROSPHERE$203
- TEZSPIRE$203
- Da Vinci Surgical System$134
- FARXIGA$102
- BREZTRI$101
How this compares
$5,231 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 341 | $256,421 |
| Breo ElliptaFluticasone/Vilanterol | 194 | $85,621 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 89 | $64,596 |
| Spiriva RespimatTiotropium Bromide | 74 | $43,188 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $25,841 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $16,731 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $16,126 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $14,715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 562 | $13,557 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $12,720 |
| Arnuity ElliptaFluticasone Furoate | 61 | $11,722 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $8,348 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 38 | $7,596 |
| Ventolin HfaAlbuterol Sulfate | 106 | $6,408 |
| EliquisApixaban | 11 | $6,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $951 | $396,337690 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $666 | $80,721150 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $430 | $55,908101 claims |
| PfizerEliquis | $221 | $6,22711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Fayetteville
- Shelby CochranFayetteville$23K
- Margaret OliverFayetteville$12K
- Christopher TitsworthFayetteville$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.